Success Metrics

Clinical Success Rate
76.7%

Based on 23 completed trials

Completion Rate
77%(23/30)
Active Trials
32(36%)
Results Posted
52%(12 trials)
Terminated
7(8%)

Phase Distribution

Ph phase_4
1
1%
Ph not_applicable
30
34%
Ph phase_2
34
39%
Ph phase_1
11
13%
Ph phase_3
3
3%
Ph early_phase_1
4
5%

Phase Distribution

15

Early Stage

34

Mid Stage

4

Late Stage

Phase Distribution83 total trials
Early Phase 1First-in-human
4(4.8%)
Phase 1Safety & dosage
11(13.3%)
Phase 2Efficacy & side effects
34(41.0%)
Phase 3Large-scale testing
3(3.6%)
Phase 4Post-market surveillance
1(1.2%)
N/ANon-phased studies
30(36.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

63.9%

23 of 36 finished

Non-Completion Rate

36.1%

13 ended early

Currently Active

32

trials recruiting

Total Trials

88

all time

Status Distribution
Active(35)
Completed(23)
Terminated(13)
Other(17)

Detailed Status

Recruiting25
Completed23
unknown16
Terminated7
Active, not recruiting7
Withdrawn6

Development Timeline

Analytics

Development Status

Total Trials
88
Active
32
Success Rate
76.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (4.8%)
Phase 111 (13.3%)
Phase 234 (41.0%)
Phase 33 (3.6%)
Phase 41 (1.2%)
N/A30 (36.1%)

Trials by Status

not_yet_recruiting33%
recruiting2528%
completed2326%
terminated78%
withdrawn67%
active_not_recruiting78%
suspended11%
unknown1618%

Recent Activity

Clinical Trials (88)

Showing 20 of 88 trialsScroll for more
NCT04610372Not Applicable

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Recruiting
NCT07414992Phase 2

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Not Yet Recruiting
NCT04944914Phase 3

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Recruiting
NCT05023265Not Applicable

Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

Recruiting
NCT02364557Phase 2

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Completed
NCT05534438Phase 2

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Recruiting
NCT07126158Phase 2

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Recruiting
NCT07517640Phase 2

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Not Yet Recruiting
NCT06391242Phase 3

Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases

Recruiting
NCT05674396Phase 2

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

Recruiting
NCT05403723Phase 1

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Suspended
NCT04983095Not Applicable

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

Recruiting
NCT04081428

Using Breath, Cell Free DNA and Image Analysis to PRedIct Normal TissUe and Tumour Response During Prostate Cancer SBRT

Active Not Recruiting
NCT03073278Not Applicable

Focal Radiotherapy for Previously Treated Prostate Cancer Patients

Recruiting
NCT06293157Not Applicable

Carbon Fiber Transpedicular Screws in Treatment of Spinal Metastatic Disease

Recruiting
NCT00492817Phase 1

Evaluation of Single Session Stereotactic Body Radiotherapy

Completed
NCT03693014Phase 2

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Active Not Recruiting
NCT03383302Phase 1

SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

Completed
NCT03298087Phase 2

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Completed
NCT04552509Not Applicable

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
88